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Abstract
Background: The accumulation of mutations after long-lasting exposure to a failing combination antiretroviral therapy
(cART) is problematic and severely reduces the options for further successful treatments.
Methods: We studied patients from the Swiss HIV Cohort Study who failed cART with nucleoside reverse transcriptase
inhibitors (NRTIs) and either a ritonavir-boosted PI (PI/r) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The loss
of genotypic activity ,3, 3–6, .6 months after virological failure was analyzed with Stanford algorithm. Risk factors
associated with early emergence of drug resistance mutations (,6 months after failure) were identified with multivariable
logistic regression.
Results: Ninety-nine genotypic resistance tests from PI/r-treated and 129 from NNRTI-treated patients were analyzed. The
risk of losing the activity of $1 NRTIs was lower among PI/r- compared to NNRTI-treated individuals ,3, 3–6, and .6
months after failure: 8.8% vs. 38.2% (p = 0.009), 7.1% vs. 46.9% (p,0.001) and 18.9% vs. 60.9% (p,0.001). The percentages
of patients who have lost PI/r activity were 2.9%, 3.6% and 5.4%,3, 3–6,.6 months after failure compared to 41.2%, 49.0%
and 63.0% of those who have lost NNRTI activity (all p,0.001). The risk to accumulate an early NRTI mutation was strongly
associated with NNRTI-containing cART (adjusted odds ratio: 13.3 (95% CI: 4.1–42.8), p,0.001).
Conclusions: The loss of activity of PIs and NRTIs was low among patients treated with PI/r, even after long-lasting exposure
to a failing cART. Thus, more options remain for second-line therapy. This finding is potentially of high relevance, in
particular for settings with poor or lacking virological monitoring.
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Introduction
The emergence of drug resistance is one of the major threats to
successful antiretroviral therapy of infection with human immu-
nodeficiency virus-1 (HIV-1) [1]. HIV-1 cannot be eradicated with
today’s antiretroviral treatment. The aim of therapy is thus to
reduce morbidity and mortality by long-term inhibition of HIV-1
replication. Combination antiretroviral therapy (cART) is highly
effective but viruses may start replicating if drug levels are too low
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(e.g. due to patients poor adherence or drug-drug interaction),
concurrent infections or recent vaccinations. In these situations
drug resistance mutations can accumulate [2–7]. To avoid long-
lasting episodes of viral replication under cART and to detect a
virological failure early, it is recommended to regularly monitor
plasma viral load levels [8,9]. However, in resource-limited
settings the technical equipment, health care infrastructure and
financial capacity are often lacking. Monitoring of cART is
therefore often solely based on the measurements of CD4 cell
counts. However, monitoring of treatment success by CD4 cell
counts results in a significant delay to detecting treatment failure
when compared to viral load monitoring and results in a higher
burden of mutations [10,11]. The accumulation of drug resistance-
associated mutations reduces the options for subsequent successful
second-line treatment dramatically. Therefore, it is important to
identify cART combinations that result in long-lasting protection
of the antiretroviral activity and to minimize the emergence of
drug resistance mutations even if patients need to stay extended
periods on a failing therapy [12].
We aimed to study the loss of genotypic activity at different time
points after virological failure and the accumulation of mutations.
We further sought to identify risk factors for early emergence of
mutations and we aimed to describe antiretroviral treatments with
a long-lasting protection of the genotypic activity after virological
failure. To answer these questions, we used data from the Swiss
HIV Cohort (SHCS) and the SHCS drug resistance database and
compared sequences from genotypic drug resistance tests that were
performed after patients had failed first-line cART.
Methods
Ethics statement
The SHCS has been approved by the following ethical
committees of all participating institutions: Kantonale Ethikkom-
mission Bern; Ethikkommission beider Basel; comite´ d’e´thique du
de´partement de me´dicine de Hoˆpitaux Universitaires de Gene`ve;
commission d’e´thique de la recherche clinique, Lausanne;
comitato etico cantonale, Bellinzona; Ethikkommission des
Kanton St.Gallens; and Ethik-Kommission Zu¨rich, all Switzer-
land. Written informed consent has been obtained from all
participants [13].
Study population
We compared genotypic drug resistance tests from individuals
included in the SHCS who failed first-line cART. The SHCS is a
nationwide, multicenter, clinic-based cohort with continuous
enrolment and semi-annual study visits. The last considered
follow-up was the 18 October 2011. The SHCS drug resistance
database is linked to the SHCS and includes .14,000 sequences
from genotypic drug resistance tests performed by one of the four
authorized laboratories in Switzerland [14]. Sequences are stored
in SmartGene’s (Zug, Switzerland) Integrated Database Network
System (IDNS version 3.6.6).
Patient selection and statistical analysis
We did a cross-sectional analysis and restricted our study to
individuals who started first-line cART with nucleoside reverse
transcriptase inhibitors (NRTIs) and either a ritonavir-boosted
protease inhibitor (PI/r) or a non-nucleoside reverse transcriptase
inhibitor (NNRTI) and who had a genotypic drug resistance test
performed after virological failure but before treatment change to
second-line cART. A treatment failure was defined if at least one
HIV-1 RNA was detectable ($50 copies/mL) after previous
suppression (,50 copies/mL) or when individuals did not respond
to the first-line cART for at least 180 days (no viral load ,50
copies/mL). These individuals are further termed non-responders.
If cART was changed before 90 days or if the last viral load during
cART was undetectable, it was assumed that the treatment change
was due to toxicity reasons and the next treatment was considered
for analysis.
We calculated the time with replicating virus after virological
failure until the resistance test was performed. The time with
replicating virus was defined as the time period when patients had
detectable viral loads (.50 copies/mL). If viral loads changed
between two measurements from undetectable to detectable or
vice versa, it was assumed that viruses were replicating half of the
time. We grouped individuals with ,3, 3–6 and .6 months with
replicating virus.
Characteristics were compared with Fishers exact test (categor-
ical variables) and Wilcoxon rank-sum test (continuous variables).
The loss of genotypic activity was estimated using the Stanford
algorithm (version 6.1.1). The activity of a drug was defined as lost
when the Stanford penalty score was $30 (http://hivdb.stanford.
edu/). Drug resistance associated mutations were defined by IAS-
USA [15]. Minor PI mutations were not considered for analysis.
Thymidine-analogue mutations (TAMs) were categorized in TAM
1 (M41L, L210W, T215Y) and TAM 2 (D67N, K70R, T215F,
K219E/Q).
We identified risk factors for an early accumulation of mutations
(,6 months with replicating viruses). We performed univariable
and multivariable logistic regression analyses. The following
variables were included in the multivariable model: sex, transmis-
sion group, age, subtype, square root CD4 cell and viral load at
the time when the resistance test was performed, NRTI treatment,
PI/r or NNRTI use, and the year of cART initiation. Likelihood
ratio tests did not indicate significant departures from linearity for
continuous variables.
Adherence is an additional potential confounder. Self-reported
adherence is documented only since May 2003 in the SHCS,
therefore a sensitivity analysis including adherence data was
performed with patients who failed cART after this date [16].
Not only the time with replicating virus but also the viral load
might be predictive for the number of emerging mutations,
therefore copy-years viremia was used in a sensitivity analysis
instead of the time with replicating virus [17]. Copy-years viremia
is a way to express the amount of exposure an individual has had
to the virus over a period of time (akin to pack-years of smoking).
The mean viral load of two successive measurements is multiplied
by the time they are apart.
Statistical analyses were performed with Stata 11 SE software
(StataCorp, College Station, TX, USA). All confidence intervals
were two-sided, and the level of significance was set at 0.05.
Results
Baseline characteristics
We included 129 patients with a virological failure on a
NNRTI-containing and 99 on a PI/r-containing cART (Table 1).
The fraction of non-responders (patients who did not reach ,50
copies/mL) was 20.2% and 22.2% (p= 0.745), respectively. Most
baseline characteristics were similar between groups, although PI/
r-treated patients started cART later (median: 2007 vs. 2004,
p,0.001). The co-administered NRTIs varied slightly. The most
commonly used NRTI combination in individuals treated with
NNRTIs was zidovudine (AZT) and lamivudine (3TC) (41.1%).
Most PI/r-treated patients received tenofovir (TDF) with either
3TC or emtricitabine (FTC) (45.5%, p= 0.061). The median time
with replicating virus was 144.5 days (IQR: 87.5–233) and 141
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days (IQR: 65–268) for NNRTI- and PI/r-treated patients
(p = 0.573), respectively. Individuals were categorized by the time
the resistance test was performed after virological failure: 34 and
34, 49 and 28, 46 and 37 treated with NNRTI or PI, respectively,
had a resistance test performed after ,3, 3–6 and .6 months with
replicating virus. The median time with replicating virus in the
category .6 months was similar between groups: 277.3 days
(IQR: 226–506.5) and 292 days (IQR: 234.5–428) for NNRTI-
and PI/r-treated patients (p = 0.916), respectively.
The median viral load at the time when the genotypic resistance
test was performed was considerably higher among patients
treated with a NNRTI compared to a PI/r (HIV-1 RNA: log10 3.5
copies/mL [IQR: 2.8–4.6] vs. log10 2.8 copies/mL [IQR: 2.3–
3.6], p,0.001). In addition, the copy-years viremia was also
substantially higher in patients treated with NNRTI (641.2 years *
copies/mL [IQR: 114.5–8348.1], p,0.001) compared to PI/r
(216.9 years * copies/mL [IQR: 33.9–1454.6]).
The numbers of transmitted NRTI mutations were similar in
NNRTI- and PI/r treated individuals. A resistance test had been
performed prior to any cART initiation among 146 of 228
individuals. The prevalence of transmitted NRTI mutations was
1.5% and 5.0% in PI/r and NNRTI-treated individuals
(p = 0.378), respectively. Restricting the analysis to patients with
known baseline resistance data and without transmitted drug
resistance mutations did not alter conclusions (data not shown).
Adherence data was available for 157 of 169 (92.9%) individuals
who failed cART after May 2003. Adherence was similar between
patients treated with PI/r- or NNRTI-containing cART: 76.9%
and 79.8% (p= 0.503) never missed a drug dose six months before
reporting adherence.
Loss of genotypic activity of NRTIs
The loss of genotypic activity of NRTIs was considerably higher
in patients treated with NNRTIs compared to PI/r. The loss of
genotypic activity of NRTIs was already very high ,3 months
after failure when patients had been treated with NNRTIs (38.2%)
whereas PI/r-treated patients rarely accumulated NRTI muta-
tions in this time period (8.8%, p= 0.009). The loss of genotypic
activity of NRTIs remained considerably higher among patients
treated with NNRTIs compared to PI/r also after long-lasting
exposure to the failing regimen: 46.9% vs. 7.1% (p,0.001)
between 3–6 months and 60.9% vs. 18.9% (p,0.001) after .6
months with replicating virus. The loss of activity of more than one
NRTI was quite rare in the PI/r group for all time points: 2.9%,
7.1%, 0% when compared to the NNRTI group: 14.7%
(p= 0.197), 14.3% (p= 0.474), 21.7% (p= 0.002) at ,3, 3–6 and
.6 months after failure (Figure 1 A).
We excluded non-responders (n = 48) from a sensitivity analysis.
The results remained more favorable for the PI/r group: 37.5% vs.
9.7% (p= 0.016), 38.9% vs. 9.1% (p= 0.016), 57.1% vs. 16.7%
(p= 0.003) NNRTI- and PI-treated individuals lost the activity of
$1 NRTI after ,3, 3–6, .6 months with replicating virus.
Results were confirmed if the analysis was restricted to the 113
patients who truly failed first-line cART (patients who changed a
successful cART regimen due to toxicity reasons were excluded)
although the sample size was reduced: 23.1% vs. 38.5%
(p= 0.673), 8.3% vs. 48.0% (p= 0.027), 22.2% vs. 65.6%
(p= 0.007) after ,3, 3–6, .6 months with replicating virus lost
the activity of $1 NRTI in the PI/r and NNRTI group,
respectively. The treatment with more potent NRTI combinations
could be a potential explanation for the lower accumulation of
NRTI mutations. PI/r-treated individuals received more often the
modern and well tolerated NRTI combination TDF/FTC (40.4%)
compared to NNRTI-treated individuals (17.1%). In a sensitivity
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analysis, we only included patients who were treated with the
TDF/FTC NRTI combination (n = 62). Also in this sub-group,
the loss of activity of $1 NRTI was higher in NNRTI compared
to PI/r-treated individuals, 26.1% compared to 5% (p= 0.043),
respectively.
Higher copy-years viremia among patients treated with NNRTI
would be a potential explanation for faster accumulation of
mutations. We repeated the analysis and classified patients in 3
groups based on the copy-years viremia instead of the time with
replicating virus. Each group contained 76 patients with copy-
years viremia ,115, 115–1491,.1491 years * copies/mL. The
loss of genotypic activity of $1 NRTIs was 60.6% vs. 7.0%
(p,0.001), 51.2% vs. 15.2% (p= 0.002) and 41.5% vs. 17.4%
(p= 0.064) in group 1 to 3 among NNRTI and PI/r treated
individuals, respectively. These findings demonstrate that the
higher loss of activity in NNRTI-treated patients cannot solely be
explained by a more intense viral replication.
Loss of genotypic activity of PIs and NNRTIs
The loss of genotypic activity of NNRTIs occurred very early
after treatment failure whereas the emergence of PI/r resistance
was very rare even after long-lasting exposure to failing cART.
The percentage of patients who have lost PI/r activity was 2.9%,
3.6%, 5.4% ,3, 3–6 and .6 months compared to 41.2%, 49.0%,
63.0% of those who have lost NNRTI activity (all p,0.001)
(Figure 1 B). Results were similar when individuals were
categorized according to copy-years viremia strata: 7.0% vs.
57.6%, 0% vs. 44.2%, 4.4% vs. 54.7% (all p,0.001).
Excluding non-responders or studying exclusively patients who
failed first-line treatment confirmed these results (data not shown).
Emerging mutations
The most common cause for the loss of genotypic activity of
NRTIs was the emergence of M184V. It occurred in 36.4% of
NNRTI- and in only 9.1% of PI/r-treated individuals (p,0.001).
The prevalence of additional NRTI mutations was also much
higher in the NNRTI when compared to the PI/r group: K65R
10.9% vs. 1.0% (p= 0.003), M184I 7.0% vs. 1.0% (p= 0.029),
T215Y 5.4% vs. 1.0% (p= 0.072). All other mutations had a
prevalence of ,5% in both groups (Figure 2).
The loss of NNRTI activity was mainly caused by the
emergence of K103N (27.9%), Y181C (10.9%) or G190A
(6.2%). The most common PI mutations in PI/r-treated individ-
uals were L90M (3.0%), I84V (2.0%) and M46I (2.0%).
Risk factors for the early emergence of NRTI mutations
Exposure to NNRTIs was the major risk factor for an early
accumulation of NRTI mutations. The odds ratio (OR) was 10.6
(95% CI: 3.9–29.1) and 13.3 (95% CI: 4.1–42.8) in univariable
and multivariable models, respectively. High CD4 cell count at the
time of the resistance test was the only other factor that had a weak
association with a later accumulation of NRTI mutations
(univariable OR: 0.9 (95% CI: 0.9–1.0), multivariable OR: 0.9
(95% CI: 0.8–1.0). No other factor was significantly associated in
the multivariable model (Table 2).
Discussion
We showed that cART containing PI/r results in a long-lasting
protection of the activity of NRTIs and PI/r during sustained viral
Figure 1. Loss of genotypic activity. Loss of genotypic activity among patients treated with non-nucleoside reverse transcriptase inhibitors
(NNRTIs) or ritonavir-boosted protease inhibitors (PI/r). A) Loss of activity of 1 NRTI (open bar section) or .1 NRTIs (hatched bar section). B) Loss of
activity of a NNRTI or PI/r. 95% confidence intervals are indicated. *** Fisher exact p,0.001, ** p,0.01.
doi:10.1371/journal.pone.0050307.g001
Figure 2. Emergence of mutations. Accumulation of nucleoside
reverse transcriptase inhibitor (NRTI) mutations after virological failure
on combination antiretroviral therapy containing A) non-nucleoside
reverse transcriptase inhibitors (NNRTIs) or B) ritonavir-boosted
protease inhibitors (PI/r): K65R, M184I/V, thymidine analogue mutations
(TAM) 1 or 2, and other NRTI mutations defined by IAS-USA [15]. 95%
confidence intervals are indicated.
doi:10.1371/journal.pone.0050307.g002
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replication under therapy. In contrast, if patients are treated with
NNRTI-based cART, NRTI mutations emerge much earlier and
in larger numbers. These findings are of importance both, for
resource-rich and resource-limited settings. In resource-rich
settings, treatment failures are usually diagnosed quite early
because of frequent viral load monitoring. In resource-limited
settings patients often stay a long time on a failing regimen due to
lacking or only infrequent viral load monitoring. In both
situations, more options remain for second-line treatment if
patients receive a PI/r-based cART as first-line therapy.
Previous randomized and observational studies showed that the
failure rate between PI/r and NNRTI is comparable in most cases
but fewer mutations emerge when patients fail a PI/r treatment
[14,18–21]. Mainly the activity of PI/r is well protected but also
the activity of NRTIs [21–25]. In extension to these earlier data,
we demonstrated in our study that this effect is long-lasting. After
more than 6 months sustained viral replication on PI/r-containing
cART, the loss of activity of $1 NRTI is only 18.9% compared to
60.9% on NNRTI-containing cART. This finding is of particular
interest for resource-limited settings without virological monitoring
where high numbers of NRTI mutations, mainly M184V, and
NNRTI mutations are common in first-line failures treated with
NNRTI-containing cART [26–28]. The number of accumulating
mutations can be reduced when virological monitoring is
performed [10,29]. However, in many settings infrastructure and
costs do not allow virological monitoring at regular intervals [12],
therefore the use of PI/r as first-line therapy might be an
interesting alternative in order to save more options for second-
line treatment. Although drug resistance is an important factor to
be considered, co-formulations, simplicity of administration, costs,
drug-drug interactions, toxicity and adverse events need also to be
taken into account for the choice of first-line treatment [8].
In general, it is astonishing how few mutations were observed
overall in the 228 patients of the study who have failed therapy.
Only 43% of patients had any drug resistance-associated mutation
detected [21]. Missing drug pressure due to poor adherence could
be a possible explanation for the low prevalence of mutations but it
is probably not the major reason because .75% of patients
reported to have an excellent adherence. Nevertheless, the
prevalence of resistance might be underestimated. Currently used
genotypic resistance tests have a population detection limit of only
,20%. Additional resistant virus variants might be present at
lower levels [30–33]. The late and rare occurrence of PI/r
mutations can be explained by their high genetic barrier compared
to NNRTIs [34]. However, the mechanism explaining the lack of
resistance to co-administered NRTIs remains unknown. It can be
speculated that the two drug classes may have different activities in
different anatomical compartments [35], with regards to free
versus cell-cell virus transmission [36] so that the activity of PI/r
might be sufficient to suppress NRTI resistant strains to
undetectable levels [21]. It could also be possible that NNRTIs,
as they target the same gene as NRTIs, might select for yet
unidentified compensatory mutations in the RT connection-,
respectively, RNase H-domain of the pol gene [37,38], subse-
Table 2. Univariable and multivariable logistic regression analyzing risk factors for an early (,6 months with replicating viruses)
emergence of $1 nucleoside reverse transcriptase (NRTI) mutations (n = 145).
Characteristics
Individuals with $1 NRTI
mutation/failures (%)
Univariable odds
ratio (95% CI) P
Multivariable odds
ratio (95% CI) P
Sex
male 30/95 (31.6%) 1 (Ref) 1 (Ref)
female 15/50 (30.0%) 0.9 (0.4–2.0) 0.845 1.3 (0.5–3.5) 0.663
Transmission group
non-IDU 39/131 (29.8%) 1 (Ref) 1 (Ref)
IDU 6/14 (42.9%) 1.8 (0.6–5.4) 0.319 2.4 (0.5–12.0) 0.274
Age 1.0 (0.9–1.0) 0.343 1.0 (0.9–1.0) 0.175
Subtype
non-B 15/59 (25.4%) 1 (Ref) 1 (Ref)
B 30/86 (34.9%) 1.6 (0.8–3.3) 0.228 1.6 (0.6–4.4) 0.401
ffiffiffiffiffiffiffiffiffiffi
CD4
p
cells/mL 0.9 (0.9–1.0) 0.014 0.9 (0.8–1.0) 0.024
log10 HIV RNA 1.5 (1.1–2.1) 0.013 1.0 (0.6–1.5) 0.907
NRTI backbone
3TC TDF 8/14(57.1%) 1 (Ref) 1 (Ref)
FTC TDF 8/42(19.1%) 0.2 (0.0–0.7) 0.009 0.3 (0.1–1.8) 0.195
ABC 3TC 4/21(19.1%) 0.2 (0.0–0.8) 0.025 0.2 (0.0–1.3) 0.093
AZT 3TC 15/46(32.6%) 0.4 (0.1–1.2) 0.105 0.4 (0.1–1.9) 0.222
other 10/22(45.5%) 0.6 (0.2–2.4) 0.495 0.5 (0.1–2.9) 0.460
Second drug class
PI/r 5/62 (8.1%) 1 (Ref) 1 (Ref)
NNRTI 40/83 (48.2%) 10.6 (3.9–29.1) ,0.001 14.3 (4.3–47.5) ,0.001
Year of cART start 0.9 (0.8–1.0) 0.010 1.0 (0.8–1.2) 0.698
Abbreviation: CI, confidence interval; IDU, intravenous drug user; FTC, emtricitabine; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; TDF, tenofovir; PI/r, ritonavir-
boosted protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0050307.t002
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quently leading to more rapid emergence of NRTI mutations
[39,40]. In theory, the presence of minority variants harboring
NNRTI- or NRTI-drug resistant mutations, which have been
detected in drug naive HIV-1 infected patients, could have a more
severe impact in a regimen that contains a ‘‘low genetic barrier’’
drug rather than a PI/r. This aspect cannot be excluded in the
present study. [32,41]. Poorer adherence in the PI/r-treated group
could also possibly explain the differences (no selective drug
pressure from NRTIs) but adherence was excluded as potential
bias in a sensitivity analysis. In addition, different NRTI
backbones in PI/r- and NNRTI-treated individuals might have
influenced our results [42,43]. To disprove this concern, we
performed a sensitivity analysis only including patients with a
TDF/FTC backbone and we adjusted the logistic regression for
the NRTI backbone.
Although our study initially considered 5959 patients who
started first-line cART, only 228 individuals qualified for our
study. The sample size was too small to compare different
treatment regimens in more detail. Unfortunately, sufficient
longitudinal resistance data from our patients were not available;
otherwise dynamics of evolution of individual drug resistance
mutations could have been investigated in more detail. In
addition, we cannot exclude that there are resistance associated
mutations outside the sequenced region. No phenotypic resistance
tests were available that could prove that viruses which do not
harbor any mutations are really sensitive to the drugs.
In conclusion, PI/r containing cART leads to long-lasting
protection of the activity of NRTIs and PI/r despite ongoing viral
replication after virological failure. Accumulation of drug resis-
tance mutations against all three drugs of the regimen is slower
and less frequent when compared to NNRTI-containing regimens,
thus retaining more options for second-line therapy. These
findings are of high relevance for settings, which lack the
opportunities for regular virological monitoring and where the
use of PI/r as first-line therapies should be considered.
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